Skip to main content

Advertisement

SpringerLink
Log in

TET2 Single Nucleotide Polymorphism in Myeloid Neoplasms Among Egyptian Patients

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Acute myelogenous leukemia (AML) is a heterogeneous disease characterized by myeloid progenitor cells uncontrolled proliferation gradually replacing normal hematopoiesis. To evaluate Ten Eleven Translocation 2 gene (TET2) single nucleotide polymorphism (SNP) (rs2454206, rs34402524, rs61744960) in AML, and chronic myeloid leukemia (CML) in relation to their disease prognostic criteria. The study included 136 subjects; 52 AML, 54 CML and 30 subjects as control group matched for age and sex. Routine investigations including CBC, bone marrow aspiration, flow cytometry biochemical investigations and cytogenetics and molecular study were performed accordingly. DNA extraction and SNP assay for TET2 gene polymorphism was done using (Thermo-Fisher predesigned SNP, USA) PCR prism 7500. The mean age was 43.4 ± 14.0 years in AML patients, 45.98 ± 15.7 years in CML patients and 39.3 ± 6.587 years in control group (p > 0.05). The frequency of TET2 SNP rs 34402524 ranged from heterozygous to homozygous in both AML (46%, 54%) and CML (48%, 46.2%) groups but was mainly homozygous among the control (80%) group (p = 0.012). TET2 SNP rs 2454206 was mainly wild in CML (65.4%) and control (63.3%) groups compared to AML as wild was only in (46%) and heterozygous in (44%) with only 10% being homozygous (p = 0.046). TET2 SNP rs 61744960 showed a homozygous pattern among all three group (AML CML and control) showing no statistical significance (p = 0.528). Eventhough, higher non responders to treatment were among homozygous and heterozygous groups yet, response to therapy as respect to specific TET2 SNP showed no significant variation (p > 0.05). TET2 SNP in CML cases did not alter the prognostic criteria as no statistical significance was noted (p > 0.05) except for TET2 SNP rs 34402524 where homozygous cases had larger spleen size (p = 0.019). TET2 SNP is common in Egyptian myeloid neoplasm. This is the first study in this field and further studies are recommended to investigate TET2 and relation to other hematological malignancies and leukemogenesis transformation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of Data and Materials

All data are in the possession of corresponding author and were presented in figure and tables and materials of study were executed in both Medical Genetics Center and Clinical Pathology in Faculty of Medicine, Alexandria University.

References

  1. Smith BD, Sung L (2013) Acute myeloid leukemia. Blood 5(18):481–489

    Google Scholar 

  2. Dolnik A et al (2012) Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 120(18):e83–e92

    Article  CAS  Google Scholar 

  3. Marcucci G, Haferlach T, Dohner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29(5):475–486

    Article  CAS  Google Scholar 

  4. Appelbaum FR et al (2006) Age and acute myeloid leukemia. Blood 107(9):3481–3485

    Article  CAS  Google Scholar 

  5. Solary E et al (2013) Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28(3):1–36

    Google Scholar 

  6. Ko M, Rao A (2011) TET2: epigenetic safeguard for HSC. Blood 118(17):4501–4503

    Article  CAS  Google Scholar 

  7. Albano F et al (2011) Decreased TET2 gene expression during chronic myeloid leukemia progression. Leukemia Res 35(11):e220–e222

    Article  CAS  Google Scholar 

  8. Mohr F et al (2011) TET genes: new players in DNA demethylation and important determinants for stemness. Exp Hematol 39(3):272–281

    Article  CAS  Google Scholar 

  9. Ko M et al (2011) Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci 108(35):14566–14571

    Article  CAS  Google Scholar 

  10. Tan L, Shi YG (2012) Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 139:1895–1902

    Article  CAS  Google Scholar 

  11. Ismail S, Essawi M (2012) Genetic polymorphism studies in humans. Middle East J Med Genet 1(2):57–63

    Article  Google Scholar 

  12. Chou WC et al (2011) TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 118(14):3803–3810

    Article  CAS  Google Scholar 

  13. Solary E et al (2014) The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28(3):485–496

    Article  CAS  Google Scholar 

  14. Hamed AMN et al (2018) Ten Eleven Translocation Gene 2 (TET2) polymorphism in acute myeloid leukemia. Ann Adv Med Sci 2(2):A49–A53

    Google Scholar 

  15. Kutny MA et al (2015) Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children/'s Oncology Group. Leukemia 29(12):2424–2426

    Article  CAS  Google Scholar 

  16. Hamed N et al (2015) TET2 expression in a cohort of Egyptian acute myeloid leukemia patients. Egypt J Haematol 40:159–165

    Article  Google Scholar 

  17. Li M-J et al (2011) Prevalence and prognosis value of TET2 gene polymorphisms in childhood acute myeloid leukemia in Taiwan. Blood 118(21):1551

    Article  Google Scholar 

  18. Nibourel O et al (2010) Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 116(7):1132–1135

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Special thanks to Hematology Department all physicians, nurses and paramedics whom actively participated in this work. Special thanks to the Medical Genetics Center technicians who were keen and dedicated to this work. Lastly but not least special thanks to the Clinical Pathology Department Hematology section team whose participation founded the basic steps in this work.

Funding

The research was fully funded by the corresponding author only.

Author information

Authors and Affiliations

  1. Hematology Department, Internal Medicine, Faculty of Medicine, Taiz University, Taiz, Yemen

    Enas A. Dammag

  2. Hematology Department, Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Nahla A. M. Hamed & Nabil A. Elhalawani

  3. Medical Genetics Center, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Heba S. Kassem

  4. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Mona W. Ayad

Authors
  1. Enas A. Dammag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nahla A. M. Hamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nabil A. Elhalawani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heba S. Kassem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mona W. Ayad
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ED corresponding author funded, selected patients and data, participated in the lab work for molecular study, and followed up cases after induction/remission cycle. NAMH and NAE suggested the field of research, supervised, monitored and guided the research. HSK Medical Genetics Center performed the molecular study on TET2 polymorphism. MWA Clinical Pathology performed the routine diagnostic tests including biochemical tests bone marrow aspiration immunophenotyping and cytogenetics analysis.

Corresponding author

Correspondence to Enas A. Dammag.

Ethics declarations

Conflict of interests

All authors declare that they have no conflict of interest.

Ethical Approval

All procedures in this research was subjected to the ethical regulation of ethical committee and approval of the Ethical committee of the Faculty Of Medicine–Alexandria University according to ICH GCP guidelines and applicable local and institutional regulations and guidelines governing EC operation (IRB No. 00008699, FWA No. 00015712) full-filling the 1964 Helsinki declaration.

Informed Consent

Written Informed consent was taken from every patient. All authors certify that they have seen and approved the final version of the manuscript being submitted. They warrant that the article is the authors' original work, hasn't received prior publication and isn't under consideration for publication elsewhere. There is no conflict of interest and the corresponding author is the main author whom research was done by. There is no image, video or details concerning patients requiring consent to publish.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dammag, E.A., Hamed, N.A.M., Elhalawani, N.A. et al. TET2 Single Nucleotide Polymorphism in Myeloid Neoplasms Among Egyptian Patients. Indian J Hematol Blood Transfus 36, 91–96 (2020). https://doi.org/10.1007/s12288-019-01172-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-019-01172-z

Keywords

Search

Navigation